NCT05636293View on ClinicalTrials.gov

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
Celiac Disease
Interventions
DRUG

Ritlecitinib

200mg Ritlecitinib

DRUG

Placebo

Placebo

OTHER

Gluten

10g of gluten

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT05636293 - Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission | Biotech Hunter | Biotech Hunter